Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

What You Need to Know About Prelude Fertility

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Prelude Fertility was founded in late 2016 by successful startup entrepreneur Martin Varsavsky with a $200M investment. Source: BioSpace

Continue ReadingWhat You Need to Know About Prelude Fertility

German Biotech BioNTech Locks in $270M Series A

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The Company previously completed a seed round fundraising in 2008 concurrent with its founding. Source: BioSpace

Continue ReadingGerman Biotech BioNTech Locks in $270M Series A

Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Pfizer will use Arvinas' proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Source: BioSpace

Continue ReadingPfizer, Arvinas Forge $830M Protein Degradation R&D Deal

OvaScience Pinks Slips Nearly 50% of Workforce

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

OvaScience provided a corporate update that includes initial data from a Phase I trial and news of extensive layoffs. Source: BioSpace

Continue ReadingOvaScience Pinks Slips Nearly 50% of Workforce

Neurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

The Series A financing was co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. Source: BioSpace

Continue ReadingNeurogastrx Bags $45M, a New CEO and a HQ Move to the Greater Boston Area

Generation Bio Emerges With $25M and Former Sobi CEO as Its New Leader

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology Source: BioSpace

Continue ReadingGeneration Bio Emerges With $25M and Former Sobi CEO as Its New Leader

Novartis' New Year Continues With Second FDA Breakthrough Tag of the Week

  • Post author:Sam
  • Post published:January 3, 2018
  • Post category:BioPharma

A Novartis drug approved as a second-line treatment for a blood disorder snagged the FDA's Breakthrough Therapy Designation as a first-line defense. Source: BioSpace

Continue ReadingNovartis' New Year Continues With Second FDA Breakthrough Tag of the Week

Spark's Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The therapy is the first type approved by the FDA that targets a disease caused by mutations in a specific gene. Source: BioSpace

Continue ReadingSpark's Blindness-Curing Gene Therapy Comes With a $850,000 Price Tag

FDA Hails Novartis' Kisqali a Breakthrough

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial. Source: BioSpace

Continue ReadingFDA Hails Novartis' Kisqali a Breakthrough

Addex, Indivior Forge $335M Addiction Disorder Tie-Up

  • Post author:Sam
  • Post published:January 2, 2018
  • Post category:BioPharma

Indivior today announced that Indivior UK Limited has entered into a strategic collaboration with Addex, in the field of GABAB PAMs. Source: BioSpace

Continue ReadingAddex, Indivior Forge $335M Addiction Disorder Tie-Up
  • Go to the previous page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 288
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.